Outcome of Low-Dose Palliative Radiation Therapy in Relapsed or Refractory High-Grade Non-Hodgkin Lymphoma

Abstract

690,550), a JAK3 inhibitor, ionizing radiation (IR) or in combination. Apoptosis was studied using Annexin V apoptosis detection assay. JAK-STAT phosphorylation patterns post treatment was studied using immunoblotting. Results: Cell viability assays showed that the addition of low dose tofacitinib (200 nM) in both cell lines to low dose (2 Gy) Ionizing Radiation (IR) increased tumor cell death by 2-folds. Combined treatment of IR and tofacitinib increased apoptosis in contrast to treatment with IR or tofacitinib alone. Reduction of downstream JAK-STAT phosphorylation (pSTAT1, pSTAT3, and pSTAT5) was more pronounced in the combined treatment group as compared to IR alone. Conclusion: We were able to demonstrate that abrogation of JAK-STAT pathway through JAK inhibition resulted in improved radiation induced cell death. This was associated with increased apoptosis and down regulation of downstream STATs phosphorylation. A molecularly targeted approach against the JAK-STAT pathway in combination with RT may prove to have clinical utility in future.

Dramatic radiotherapy response in a necrotic lymphoma mass: a case report

“…Doses as low as 4 Gray (Gy) delivered over two fractions have been shown to result in 50-80% response rates for DLBCL at 21 days [6,7], with a median time to disease progression following radiotherapy of 12 months [6]. Treatment with hypofractionated schedules (dose > 2 Gy per fraction), including 8 Gy in a single fraction, have also been used in this setting to provide effective symptom control, with minimal toxicity and inconvenience to patients [8,9]. Higher-dose hypofractionated schedules with total doses of 8-30 Gy are recommended in the International Lymphoma Radiation Oncology Group (ILROG) guidelines [10].…”